FDA's Slow Track Dilemma: Nicotine Pouches Under Scrutiny

The sale of popular nicotine pouch products in the United States faces delays, despite efforts from the Food and Drug Administration (FDA) to fast-track approvals. According to sources, agency scientists are hesitant to authorize these products due to potential risks for new users, especially children.

New nicotine products such as pouches, inserted under the lip for a nicotine buzz, require FDA authorization for legal sale in the U.S. This market, valued at approximately $22 billion, has seen significant growth, with many users switching from smoking to these alternatives. Despite the FDA's plans to expedite decisions through a pilot program, challenges remain.

The FDA continues to balance the potential benefits of nicotine pouches for smokers against the risks posed to non-users and youth. As the agency weighs its decisions, leading companies like Philip Morris International and British American Tobacco await approvals, with their shares showing mixed reactions to ongoing developments.